Restoration of defective EAG-rosetting capacity of cancer patient neutrophils by levamisole.
Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the "immunomodulating" effect of the drug.
D002462:Cell Membrane / Q000276:immunology; D005770:Gastrointestinal Neoplasms / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D007978:Levamisole / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000276:immunology*; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D011961:Receptors, Fc / Q000032:analysis; D012397:Rosette Formation
D011961:Receptors, Fc; D007978:Levamisole